Medicus Pharma Ltd. has announced an expansion of its Phase 2 clinical study for SKNJCT-003, which began randomizing patients in August 2024 across nine clinical sites in the United States. Following a positively trending interim analysis in March 2025, showing over 60% clinical clearance, the investigational review board has increased the number of study participants to 90 subjects. The interim results are preliminary and may not necessarily reflect the final study outcomes. Additionally, the company is expanding its clinical trial sites into Europe. The lead asset, SkinJect Inc., focuses on a novel treatment for non-melanoma skin cancer using a patented dissolvable doxorubicin-containing microneedle array. Furthermore, Medicus Pharma Ltd. will present at the BTIG Virtual Biotech Conference 2025, where Dr. Raza Bokhari, Executive Chairman and CEO, will participate in a fireside chat on July 30, 2025. The chat will be livestreamed for registered investors, and a recording will be available for conference attendees.